Bio-Rad Laboratories, Inc.
General ticker "BIO" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $7.8B (TTM average)
Bio-Rad Laboratories, Inc. follows the US Stock Market performance with the rate: 43.0%.
Estimated limits based on current volatility of 1.3%: low 316.50$, high 325.15$
Factors to consider:
- Total employees count: 7700 as of 2024
- US accounted for 40.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Geopolitical risks, Regulatory and compliance, Cybersecurity threats, Organizational changes, Climate change and natural disasters
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [228.60$, 394.03$]
- 2025-12-31 to 2026-12-31 estimated range: [231.56$, 400.52$]
Financial Metrics affecting the BIO estimates:
- Negative: with PPE of 31.8 at the end of fiscal year the price was very high
- Positive: 7.86 < Operating profit margin, % of 10.48
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: 0.33 < Operating cash flow per share per price, % of 4.92
- Positive: Industry inventory ratio change (median), % of -1.44 <= -0.15
- Positive: -4.48 < Investing cash flow per share per price, % of -1.73
Short-term BIO quotes
Long-term BIO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2,802.20MM | $2,671.20MM | $2,566.50MM |
| Operating Expenses | $2,319.60MM | $2,333.40MM | $2,297.50MM |
| Operating Income | $482.60MM | $337.80MM | $269.00MM |
| Non-Operating Income | $-5,186.80MM | $-1,187.90MM | $-2,611.50MM |
| Interest Expense | $38.10MM | $49.40MM | $48.90MM |
| R&D Expense | $256.90MM | $247.40MM | $295.90MM |
| Income(Loss) | $-4,704.20MM | $-850.10MM | $-2,342.50MM |
| Taxes | $-1,076.70MM | $-212.80MM | $-498.30MM |
| Profit(Loss)* | $-3,627.53MM | $-637.32MM | $-1,844.20MM |
| Stockholders Equity | $9,615.25MM | $8,741.20MM | $6,569.30MM |
| Inventory | $719.32MM | $780.50MM | $760.00MM |
| Assets | $13,501.67MM | $12,299.10MM | $9,364.10MM |
| Operating Cash Flow | $194.45MM | $374.94MM | $455.20MM |
| Capital expenditure | $114.16MM | $156.68MM | $189.00MM |
| Investing Cash Flow | $-1,207.59MM | $20.21MM | $-160.20MM |
| Financing Cash Flow | $973.58MM | $-425.65MM | $-218.80MM |
| Earnings Per Share** | $-121.79 | $-21.82 | $-65.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.